2012

• Ngan, S., Burmeister, B., Fisher, R., Solomon, M., Goldstein, D., Joseph, D., Ackland, S., Schache, D., McClure, B., McLachlan, S., McKendrick, J., Leong, T., Hartopeanu, C., Zalcberg, J., Mackay, J. (2012), Randomized Trial of Short-Course Radiotherapy Versus Long-Course Chemoradiation Comparing Rates of Local Recurrence in Patients With T3 Rectal Cancer: Trans-Tasman Radiation Oncology Group Trial 01.04. Journal of Clinical Oncology. 30(31), 3827-3833. [Abstract]

2011

• Sjoquist, K., Burmeister, B., Smithers, B., Zalcberg, J., Simes, R., Barbour, A., Gebski, V. (2011), Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. The lancet oncology. 12(7), 681-92. [Abstract]
• Cameron, A., Sjoquist, K., Zalcberg, J. (2011), Controversies in oesophagogastric cancer. Cancer Forum. 35(3), 139-141.

2010

• Field, K., Zalcberg, J. (2010), Chemotherapy: Metastatic Disease. In: Rectal Cancer: International Perspectives on Multimodality Management. (pp.189-222).United States: Springer Science+Business Media.

2009

• Au, H., Karapetis, C., O'Callaghan, C., Tu, D., Moore, M., Zalcberg, J., Kennecke, H., Shapiro, J., Koski, S., Pavlakis, N., Charpentier, D., Wyld, D., Jefford, M., Knight, G., Magoski, N., Brundage, M., Jonker, D. (2009), Health-related quality of life in patients with advanced colorectal cancer treated with cetuximab: overall and KRAS-specific results of the NCIC CTG and AGITG CO.17 Trial. Journal of Clinical Oncology. 27(11), 1822-1828. [Abstract]
• Michael, M., Price, T., Ngan, S., Ganju, V., Strickland, A., Muller, A., Khamly, K., Milner, A., Dilulio, J., Matera, A., Zalcberg, J., Leong, T. (2009), A phase I trial of Capecitabine+Gemcitabine with radical radiation for locally advanced pancreatic cancer. British journal of cancer. 100(1), 37-43. [Abstract]
• Mittmann, N., Au, H., Tu, D., O'Callaghan, C., Isogai, P., Karapetis, C., Zalcberg, J., Evans, W., Moore, M., Siddiqui, J., Findlay, B., Colwell, B., Simes, J., Gibbs, P., Links, M., Tebbutt, N., Jonker, D. (2009), Prospective Cost-Effectiveness Analysis of Cetuximab in Metastatic Colorectal Cancer: Evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 Trial. Journal of the National Cancer Institute. 101, 1182-1192. [Abstract]

2008

• Karapetis, C., Khambata-Ford, S., Jonker, D., O'Callaghan, C., Tu, D., Tebbutt, N., Simes, R., Chalchal, H., Shapiro, J., Robitaille, S., Price, T., Shepherd, L., Au, H., Langer, C., Moore, M., Zalcberg, J. (2008), K-ras mutations and benefit from cetuximab in advanced colorectal cancer. The New England journal of medicine. 359(17), 1757-65. [Abstract]
• Van Cutsem, E., Dicato, M., Haustermans, K., Arber, N., Bosset, J., Cunningham, D., De Gramont, A., Diaz-Rubio, E., Ducreux, M., Goldberg, R., Glynne-Jones, R., Haller, D., Kang, Y., Kerr, D., Labianca, R., Minsky, B., Moore, M., Nordlinger, B., Rougier, P., Scheithauer, W., Schmoll, H., Sobrero, A., Tabernero, J., Tempero, M., Van de Velde, C., Zalcberg, J. (2008), The diagnosis and management of rectal cancer: expert discussion and recommendations derived from the 9th World Congress on Gastrointestinal Cancer, Barcelona, 2007. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 19 Suppl 6, vi1-8. [Abstract]
• Zalcberg, J., Rosen, L., Abdi, E., Davis, I., Gutheil, J., Schnell, F., Cesano, A., Gayko, U., Chen, M., Clarke, S. (2008), Role of palifermin in fluorouracil-based therapy for metastatic colorectal cancer. Journal of Clinical Oncology. , 1386-1387. [Abstract]

2007

• Jonker, D., O'Callaghan, C., Karapetis, C., Zalcberg, J., Tu, D., Au, H., Berry, S., Krahn, M., Price, T., Simes, R., Tebbutt, N., van Hazel, G., Wierzbicki, R., Langer, C., Moore, M. (2007), Cetuximab for the Treatment of Colorectal Cancer. The New England journal of medicine. 357(20), 2040-2048. [Abstract]